Characteristics of 123 pediatric patients with chronic rheumatic diseases on bDMARD.
| Disease | |
| JIA | 89 (72.3) |
| Oligoarticular | 60 (48.8) |
| Polyarticular, RF-negative | 14 (11.4) |
| Polyarticular, RF-positive | 0 |
| Enthesitis-related arthritis | 4 (3.3) |
| Systemic JIA | 7 (5.7) |
| Psoriatic | 4 (3.3) |
| Autoinflammatory diseases | 5 (4.1) |
| Chronic uveitis | 5 (4.1) |
| Recurrent pericarditis | 2 (1.6) |
| Other | 22 (17.9) |
| Female | 83 (62.4) |
| Disease duration, yrs, median (IQR) | 6 (3–10) |
| bDMARD | |
| Anti-TNF | 95 (77.2) |
| Etanercept | 38 (30.9) |
| Adalimumab | 53 (43.1) |
| Infliximab | 4 (3.3) |
| Anakinra | 7 (5.7) |
| Tocilizumab | 7 (5.7) |
| Canakinumab | 2 (1.6) |
| Baricitinib | 1 (0.8) |
| Other | 11 (8.9) |
| Concomitant cDMARD | |
| Methotrexate | 77 (62.7) |
| Colchicine | 3 (2.4) |
| Cyclosporine | 1 (0.8) |
| Mycophenolate mofetil | 1 (0.8) |
| Systemic steroids | 6 (4.9) |
| Confirmed COVID-19 infection | 0 |
| Suspected COVID-19 infection | 0 |
| Children with mild respiratory symptoms | 8a |
Values are expressed as number (%) unless otherwise indicated.
↵aThree of them had adult family members suspected of having COVID-19. bDMARD : biologic disease-modifying antirheumatic drug; cDMARD: conventional disease-modifying antirheumatic drug; COVID-19: coronavirus disease 2019; JIA: juvenile idiopathic arthritis; RF: rheumatoid factor; TNF: tumor necrosis factor.